Ameriprise’s CalciMedica CALC Stock Holding History

Ameriprise’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-879	Closed	-$67K	–	3869
2021 Q2	$67K	Buy	+879	New	+$57.7K	﹤0.01%	3847

Other funds holding CALC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's CALC Position: Q3 2021 in Review

Ameriprise sold out of CalciMedica (CALC) in Q3 2021, closing a stake of 879 shares — an estimated $67K sold.

Ameriprise first reported a position in CALC in Q2 2021 and held it in 1 quarter. The position peaked at $67K in Q2 2021. 27 funds tracked by Wall St. Rank hold CALC as of Q3 2021.

Ameriprise reported no remaining CalciMedica position as of Q3 2021 after selling out during the quarter.
Ameriprise sold 879 CalciMedica shares in Q3 2021, an estimated $67K.
Ameriprise first reported a position in CalciMedica in Q2 2021 and held it in 1 quarter.
Ameriprise's CalciMedica position peaked at $67K in Q2 2021.
27 funds tracked by Wall St. Rank held CalciMedica as of Q3 2021.

Based on Ameriprise's 13F filing for Q3 2021, filed 15 Nov 2021.